Strumento inattivo

Altre lingue Blue Water Ventures International Inc Other OTC

Azioni

US8317182009

Prezzo di chiusura Other OTC Altri mercati azionari
- ^USD	-

2023	Psycheceutical Bioscience, Inc. annuncia cambiamenti nell'Amministratore Delegato	CI
2023	Psycheceutical Bioscience, Inc. nomina Neilank K. Jha come suo nuovo Presidente Esecutivo	CI

Altre lingue

Sblocca tutte le notizie su tutte le aziende: non perdere mai più un'opportunità di investimento redditizia!

Registrazione 100% gratuita

Psycheceutical Bioscience, Inc. Announces Chief Executive Officer Changes	12/12
Psycheceutical Bioscience, Inc. Appoints Neilank K. Jha as Its New Executive Chairman	12/12
Blue Water Ventures International, Inc. announced that it expects to receive $5 million in funding	26/09/23
Psycheceutical Bioscience, Inc Announces First Patient Has Been Dosed in Its Phase I Study to Evaluate Its Patented Neurodirectâ„¢ Ketamine Topical Delivery System for the Treatment of Post Traumatic Stress Disorder	13/07/23
Veru Sells ENTADFI Business for $20 Million Plus up to an Additional $80 Million from Sales Milestones	21/04/23
Psycheceutical Bioscience, Inc. Named a 2023 Top 10 Biotech Startup by Life Sciences Review	13/04/23
Psycheceutical Hosts MAPS Founder and Psychedelic Industry Leader Rick Doblin at Its Drug Development Lab	29/03/23
Psycheceutical Bioscience, Inc. Announces Observational Research Results for NeuroDirect™ Ketamine Topical Cream in Treating PTSD	21/03/23
Psycheceutical Bioscience, Inc. Announces Observational Research Results for NeuroDirect™ Ketamine Topical Cream in Treating PTSD	21/03/23
Psycheceutical Bioscience, Inc. Announces Publication of Pre-Clinical Observational Data Supports Potential of its NeuroDirect™ Ketamine Topical Cream as Treatment for PTSD	21/03/23
Psycheceutical to Conduct the First Ever Phase I and II Clinical Trials of a Novel Ketamine Topical Cream to Treat PTSD	15/02/23
Psycheceutical to Conduct the First Ever Phase I and II Clinical Trials of a Novel Ketamine Topical Cream to Treat PTSD	15/02/23
Psycheceutical to Conduct the First Ever Phase I and II Clinical Trials of a Novel Ketamine Topical Cream to Treat PTSD	15/02/23
Psycheceutical Announces Completion of Pre-IND Meeting with FDA for Topical Ketamine Drug to Treat PTSD	02/02/23
Psycheceutical Announces Completion of Pre-IND Meeting with FDA for Topical Ketamine Drug to Treat PTSD	02/02/23
Psycheceutical Bioscience Provisional Patent Application for Novel Ketamine Topical for the Treatment of PTSD	26/01/23
Psycheceutical Bioscience Provisional Patent Application for Novel Ketamine Topical for the Treatment of PTSD	26/01/23
Psycheceutical Announces Julian Bailes, M.D. as Board Member and Chief Medical Officer	10/01/23
Psycheceutical Announces Julian Bailes, M.D. as Board Member and Chief Medical Officer	10/01/23
Dr. Aric Logsdon Joins Psycheceutical Bioscience, Inc. as Company’s Scientific Director	29/11/22

Non ci sono risultati per questa ricerca

Tutte le notizie Raccomandazione analisti Eventi più importanti Insiders Resoconti Comunicati stampa Pubblicazioni ufficiali Altre lingue Idee di trading Articoli MarketScreener Analisi MarketScreener

Altre lingue Blue Water Ventures International Inc Other OTC

Azioni

US8317182009

Altre lingue

Filtri